TransMedics Group, Inc. (NASDAQ:TMDX) Insider Nicholas Corcoran Sells 10,000 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now owns 21,105 shares in the company, valued at $3,714,902.10. The sale was disclosed in a document filed with the SEC, which is available through this link.

TransMedics Group Trading Down 1.4 %

Shares of TMDX traded down $2.35 during mid-day trading on Thursday, hitting $166.65. The company’s stock had a trading volume of 368,178 shares, compared to its average volume of 760,243. The firm has a 50-day simple moving average of $153.15 and a 200 day simple moving average of $121.25. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same period in the prior year, the company posted ($0.03) EPS. The business’s revenue for the quarter was up 117.7% on a year-over-year basis. On average, research analysts expect that TransMedics Group, Inc. will post 1.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TMDX. Cantor Fitzgerald began coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price for the company. Needham & Company LLC began coverage on shares of TransMedics Group in a research report on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price on the stock. Stephens increased their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. TD Cowen raised their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. Finally, Canaccord Genuity Group upped their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $171.44.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in TransMedics Group by 7.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,396 shares of the company’s stock valued at $584,000 after purchasing an additional 483 shares during the last quarter. Handelsbanken Fonder AB grew its position in shares of TransMedics Group by 44.0% in the fourth quarter. Handelsbanken Fonder AB now owns 7,200 shares of the company’s stock valued at $568,000 after purchasing an additional 2,200 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of TransMedics Group by 41.9% during the 4th quarter. New York State Common Retirement Fund now owns 87,516 shares of the company’s stock worth $6,908,000 after purchasing an additional 25,849 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of TransMedics Group during the 4th quarter worth approximately $415,000. Finally, Truist Financial Corp lifted its stake in TransMedics Group by 60.7% in the 4th quarter. Truist Financial Corp now owns 12,462 shares of the company’s stock valued at $984,000 after buying an additional 4,707 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.